As a result, therapeutic strategies involving DNA-damaging radiotherapy [23,24], genotoxins [25,26], and peptides [27] have been investigated for enhancing cancer cell sensitivity to TRAIL [25] and/or agonistic antibodies against DR4/DR5 [28]. This evidence concerns the gene TNFRSF10B and cancer.